BamSEC and AlphaSense Join Forces
Learn More

Travere Therapeutics Inc. – Material Contracts

NASDAQ: TVTX    
Share price (6/2/26): $42.96    
Market cap (6/2/26): $3.995 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 2 pages Non-Employee Director Compensation Program
12/34/56
EX-10.9
from 10-K 4 pages 2026 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan
12/34/56
EX-10.2
from 10-Q 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 2 to License and Collaboration Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Non-Employee Director Compensation Program
12/34/56
EX-10.9
from 10-K 4 pages 2025 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan
12/34/56
EX-10.1
from 10-Q 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 5 to Sublicense Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Non-Employee Director Compensation Program
12/34/56
EX-10.32
from 10-K 10 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Fifth Amendment to Trademark License and Supply Agreement
12/34/56
EX-10.30
from 10-K 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential
12/34/56
EX-10.29
from 10-K 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment One to the Third Amendment to Trademark License and Supply Agreement
12/34/56
EX-10.28
from 10-K 3 pages Third Amendment to Trademark License and Supply Agreement
12/34/56
EX-10.25
from 10-K 15 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Trademark License & Supply Agreement
12/34/56
EX-10.10
from 10-K 4 pages 2024 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan
12/34/56
EX-10.8
from 10-K 2 pages Non-Employee Director Compensation Program
12/34/56
EX-10.2
from 10-Q 30 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Asset Purchase Agreement
12/34/56
EX-10.1
from 8-K 85 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Asset Purchase Agreement by and Between Travere Therapeutics, Inc. and Mirum Pharmaceuticals, Inc. Dated as of July 16, 2023
12/34/56
EX-10.2
from 10-Q 20 pages Employment Agreement
12/34/56
EX-10.39
from 10-K 2 pages Amendment No. 1 to License and Collaboration Agreement
12/34/56
EX-10.37
from 10-K 6 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. First Amendment to Master Manufacturing Supply Agreement
12/34/56
EX-10.12
from 10-K 4 pages 2023 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan
12/34/56